Literature DB >> 11553221

Best palliation in esophageal cancer: surgery, stenting, radiation, or what?

M Frenken1.   

Abstract

Palliation of patients with obstructing or fistulizing esophageal cancer is not easy. Median survival cannot be expected to be longer than 3-6 months, regardless of which therapy is carried out. Self-expandable metal stents have revolutionized the treatment of these patients because of easy insertion, relatively low complication rates and reasonably good functional results. Plastic tubes are mainly indicated in situations in which removal may be needed. The palliative effect of external beam radiation is well established, endoesophageal brachytherapy having the advantage of delivering a high dose in a short time. More recently, there has been increasing interest in locally destructive therapies, mostly in combination with palliative radiation or radiochemotherapy. Obviously, a single best palliation for every situation does not exist. The most appropriate method to alleviate symptoms must be worked out for each individual patient depending on the specific patient situation and the specific expertise of the physician.

Entities:  

Mesh:

Year:  2001        PMID: 11553221     DOI: 10.1046/j.1442-2050.2001.00168.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  10 in total

1.  Palliative interventions for patients with incurable locally advanced or metastatic thoracic esophageal carcinoma.

Authors:  Tomoyuki Kakuta; Shin-Ichi Kosugi; Hiroshi Ichikawa; Takaaki Hanyu; Takashi Ishikawa; Tatsuo Kanda; Toshifumi Wakai
Journal:  Esophagus       Date:  2019-04-04       Impact factor: 4.230

2.  Efficacy and Safety of Fully Covered Self-Expanding Metal Stents for Malignant Esophageal Obstruction.

Authors:  Hoonsub So; Ji Yong Ahn; Seungbong Han; Kyoungwon Jung; Hee Kyong Na; Jeong Hoon Lee; Kee Wook Jeong; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung
Journal:  Dig Dis Sci       Date:  2017-11-17       Impact factor: 3.199

3.  What is the optimal management of dysphagia in metastatic esophageal cancer?

Authors:  W C Hanna; M Sudarshan; D Roberge; M David; K A Waschke; S Mayrand; T Alcindor; L E Ferri
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

4.  An Auxetic structure configured as oesophageal stent with potential to be used for palliative treatment of oesophageal cancer; development and in vitro mechanical analysis.

Authors:  Murtaza N Ali; Ihtesham Ur Rehman
Journal:  J Mater Sci Mater Med       Date:  2011-09-06       Impact factor: 3.896

5.  [Tracheal stents for esophagotracheal fistula in laryngectomy patients. Safe fixation to the tracheostoma].

Authors:  F W Spelsberg; B Wollenberg; R Weidenhagen; R A Lang; H Winter; K-W Jauch; T P Hüttl
Journal:  HNO       Date:  2009-10       Impact factor: 1.284

6.  Reconstructive and rehabilitating methods in patients with dysphagia and nutritional disturbances.

Authors:  Christiane Motsch
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

7.  Endoscopic palliation of malignant dysphagia: a challenging task in inoperable oesophageal cancer.

Authors:  I E Katsoulis; A Karoon; S Mylvaganam; J I Livingstone
Journal:  World J Surg Oncol       Date:  2006-07-04       Impact factor: 2.754

8.  Do delays between diagnosis and surgery in resectable oesophageal cancer affect survival? A study based on West Midlands cancer registration data.

Authors:  B S Kötz; S Croft; D R Ferry
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

9.  Evidence-based recommendations on upper gastrointestinal tract stenting: a report from the stent study group of the korean society of gastrointestinal endoscopy.

Authors:  Sam Ryong Jee; Joo Young Cho; Kyung Ho Kim; Sang Gyun Kim; Jun-Hyung Cho
Journal:  Clin Endosc       Date:  2013-07-31

10.  Clinical Outcomes of Upper Gastrointestinal Stents and Review of Current Literature.

Authors:  Hasan Bektaş; Bünyamin Gürbulak; Yiğit Düzköylü; Şükrü Çolak; Esin Kabul Gürbulak; Ekrem Çakar; Savaş Bayrak
Journal:  JSLS       Date:  2017 Oct-Dec       Impact factor: 2.172

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.